SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending due to buzz around potential new AI partnerships, including with Palantir and CrowdStrike, and speculation about relaxed chip policies ahead of a Trump-Xi meeting.  The community is actively discussing the implications of these partnerships for revenue and market dominance. Many are also closely watching CEO Jensen Huang's keynote for further bullish signals.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as traders react to the company's earnings beat and raised outlook, with many expressing relief and renewed confidence. Community members are discussing the potential for the stock to reach new highs, while some debate the impact of market manipulation and short positions. The stock's recovery from recent lows has also fueled bullish sentiment.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending following news of a significant investment from Nvidia, with the community buzzing about the implications for AI-driven telecommunications infrastructure and 6G technology; many believe this partnership validates Nokia's strategic shift and unlocks long-term growth potential, while some caution about potential dilution. Discussions also involve Nokia's broader role in the evolving AI and networking landscape.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Recent conversations around Rigetti Computing (RGTI) are buzzing with volatility, as the stock experiences a significant run-up. The community is debating optimal strategies amid the price surge, with some suggesting profit-taking while others point to industry peers and broader AI news as potential catalysts. Skepticism persists, with concerns raised about valuation and competition from larger companies like NVIDIA.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors digest strong earnings and raised guidance, with many seeing this as a buying opportunity despite an initial dip. Community members are focused on upcoming catalysts like potential interest rate cuts and S&P inclusion. The stock's price action and future growth potential remain key discussion points.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as investors debate its potential following recent comments from Jensen Huang regarding quantum computing and a related dip in quantum stocks; some see this as a buying opportunity, highlighting the company's existing government contracts and comparing its valuation to sector peers like $IONQ and $RGTI, while others express concern over the lack of a confirmed partnership announcement and potential manipulation.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending due to anticipation surrounding NVIDIA's GTC conference, where the company is expected to reveal a new humanoid robot and potentially announce a collaboration with NVIDIA. Community discussions revolve around the potential for a significant stock rally if the reveal is successful, while some express concerns about overvaluation and potential short-term pullbacks. The recent partnership with the Vegas Golden Knights is also generating buzz, adding to the overall excitement surrounding Richtech Robotics' future prospects in the AI and robotics sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DKNG is trending downwards amid concerns about increased competition from prediction markets and potential regulatory impacts, especially following recent news of a gambling scandal. The community is debating whether the stock is undervalued, with some seeing the dip as a buying opportunity before earnings, while others express concern over management and the company's long-term prospects in a shifting market landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming burns and airdrops, specifically mentioning an adjusted airdrop at a $2.5mil MC. Community members express bullish sentiment, highlighting the project's commitment to development, real-world utility, and revenue generation through Broke Perspective. There's also enthusiasm for contests and community engagement, with many comparing $BROKE to other successful meme coins.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as Nvidia's increased interest in quantum computing is sparking community discussion around the potential impact on the sector, though some express concern about D-Wave's specific role. Community members are debating whether Nvidia's developments will help or hinder D-Wave, while others point to the stock's recent volatility and potential government interest as key factors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Invesco NASDAQ 100 ETF (QQQM) Be on Your Investing Radar?

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary disease (COPD) did not achieve statistical significance in the primary endpoint of controlling flare-ups.COPD, also called Smoker’s Disease, is a debilitating, irreversible, and progressive disease whose exacerbations are life-threatening and can cause irreversible lung damage and even death. According to AstraZeneca, it affects 391 million people globally.The safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html">stated</a> that it will analyze the data further to understand the results.Shares of the company slipped 0.3% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:572/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_7_28_11_AM_png_b16313a518.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="572" height="62"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure> The study was aimed at evaluating the efficacy and safety of 100 mg of Fasenra in people with moderate to very severe COPD with a history of frequent COPD exacerbations and an elevated blood eosinophil count. The company enrolled patients in the trial with a history of at least two COPD exacerbations in the year before enrollment and who were current or former smokers. Patients were randomized to receive either a placebo or Fasenra while remaining on their existing therapy.“COPD, which remains a leading cause of death worldwide, is a complex, heterogeneous disease and we continue to advance other promising approaches in our pipeline to address the unmet needs of patients,” company executive Sharon Barr saidFasenra is already used to treat severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis in several countries. According to AstraZeneca, over 150,000 patients worldwide are currently taking Fasenra. In the first half of 2025, Fasenra generated $920 million in revenue, representing an 18% year-over-year increase.Separately, the company also <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-met-primary-endpoint-in-tulip-sc.html">announced</a> that its late-stage trial evaluating subcutaneous Saphnelo in patients with systemic lupus erythematosus (SLE) met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in disease activity compared to placebo. SLE is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is estimated to impact over 3.4 million people globally.AZN stock is up by 18% this year and down by about 1% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/x4-pharma-to-halve-headcount-amid-efforts-to-complete-neutropenia-trial/chDGnJwRd6P">X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease

The company stated that the safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine, and added that it will analyze the data further to understand the results.

Equity

The company stated that the safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine, and added that it will analyze the data further to understand the results.


Marvell Technology (MRVL) plunged more than 17% at market open on Friday after issuing weaker-than-expected third-quarter guidance in its fiscal second-quarter report released late Thursday, which drew swift price target cuts and&nbsp;a ratings downgrade from Wall Street.<a href="http://stocktwits.com/symbol/MRVL">Marvell’s stock</a> was among the top trending tickers on Stocktwits at the time of writing. Despite the dip in its stock price, retail sentiment around the company surged to ‘extremely bullish’ from ‘bullish’ with chatter rising to ‘extremely high’ from ‘low’ levels over the past day, according to platform data.Bank of America downgraded&nbsp;Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90, as per TheFly. The firm cited uncertainty surrounding Marvell’s role in Microsoft’s (MSFT) Maia AI accelerator and its share of Amazon’s (AMZN) next-generation 3nm project.Morgan Stanley trimmed its target on the stock to $76 from $80 while keeping an ‘Equal Weight’ rating. The firm noted that while guidance was largely in line once the sale of Marvell’s automotive Ethernet business was factored in, the data center segment “disappointed.” Morgan Stanley added that it was not surprised by the business’s “lumpiness,” but said it was unexpected that the ASIC full-year outlook continues to decline even as demand for Amazon’s Trainium processors strengthens elsewhere.&nbsp;UBS, which lowered its price target to $95 from $110,&nbsp; also pointed to “lumpiness” in Marvell’s business.&nbsp;Needham echoed similar concerns about Marvell’s next-gen XPU contracts with Amazon and Microsoft as it lowered its price target to $80 from $85, but maintained its ‘Buy’ rating on the stock.Marvell’s stock has fallen more than 41% this year and is down around 7% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-revokes-intel-samsung-sk-hynix-waivers-on-china-chip-equipment/chtTKpgRdNh">US Revokes Intel, Samsung, SK Hynix Waivers On China Chip Equipment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Marvell Hit With Downgrade, Price Target Cuts As Analysts Flag Uncertainty In Microsoft, Amazon AI Deals

Bank of America downgraded Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90.

3 Reasons Why Nasdaq ETFs Hit a Record High 

The Nasdaq hit a record high despite tariffs, as Apple's $100B U.S. push, Fed rate cut talks and chip exemptions fuel tech optimism.

Nasdaq ETF (QQQM) Hits New 52-Week High

QQQM surges to a new 52-week high, fueled by tech strength and AI-driven earnings momentum in Nasdaq.


Will Nasdaq ETFs Continue Their Rally Going Into Q2 Earnings?

QQQ, QQQM, QQEW, QQQJ and QQQE surge as Nasdaq hits highs on earnings momentum, AI optimism and rate cut hopes.

High-Yield ETFs: Big Payouts, Bigger Trade-Offs?

Here's what investors should know about covered-call single-stock ETFs.

AstraZeneca (AZN) on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html">announced</a> a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat multiple chronic diseases.Under the deal, the companies have also agreed to develop a pre-clinical small-molecule oral therapy for immunological diseases.The research will be carried out by CSPC in Shijiazhuang City and will utilize their AI-driven drug discovery platform, which uses AI to analyse the binding patterns of target proteins with existing compound molecules. The AI also helps conduct targeted optimization with the intent of selecting highly effective small molecules with excellent developability.CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.CSPC can also receive potential single-digit royalties based on annual net sales of the products.AstraZeneca, meanwhile, will have the right to exercise options for exclusive licenses to develop and commercialize worldwide candidates identified under the agreement.In March, AstraZeneca announced a $2.5 billion investment in a research and development hub in Beijing. The new agreement will further the company’s presence in China, AstraZeneca said.On Stocktwits, retail sentiment around AstraZeneca stayed within the ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1260/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_7_54_25_AM_png_1341b85d61.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1260" height="132"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up by about 14% this year but down by nearly 6% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-launches-upgraded-model-s-x-in-us-raises-prices-5000-dollars/chlicMCRRGy">Tesla Launches Upgraded Model S, X In US, Raises Prices On All Variants By $5,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer

CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.

Invesco Exchange-Traded Fund Trust II - Invesco NASDAQ 100 ETF

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$260.51
Prev Close	$258.58
Open	$259.50
Dividend Yield	N/A
50-Day Moving Average	$243.61
Beta	N/A
Avg. Volume	3.53M
PE Ratio	N/A

52-Week High	$258.77
52-Week Low	$165.72
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

QQQM
Invesco NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest QQQM News

QQQMInvesco NASDAQ 100 ETF